정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
226 | Not yet recruiting | The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients | COVID-19 Pneumonia | Drug: Co-trimoxazole Drug: Placebo |
Phase 3 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | OTHER | 94 | All | 18 Years | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
225 | Recruiting | The Role of Resistant Starch in COVID-19 Infection | COVID-19 | Drug: Dietary Supplement containing resistant starch Dietary Supplement: Placebo Starch |
Phase 3 | Yale University, University of Michigan | OTHER | 1500 | All | 19 Years | Yale University, New Haven, Connecticut, United States University of Michigan, Ann Arbor, Michigan, United States |
224 | Active, not recruiting | The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia | Covid19 | Drug: Sodium Bicarbonate | Not Applicable | Mansoura University | OTHER | 180 | All | 18 Years | Gomhoria Street, Mansoura, Outside U.S./Canada, Egypt |
223 | Not yet recruiting | The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia | COVID-19 | Drug: Imatinib Mesylate Drug: Standard of Care |
Phase 3 | Alexandria University, Science, Technology & Innovation Funding Authority (STIFA), Egypt | OTHER | 30 | All | 18 Years | |
222 | Recruiting | The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection | Covid19 | Drug: FB2001 Drug: FB2001 Placebo |
Phase 1 | Frontier Biotechnologies Inc. | INDUSTRY | 72 | All | 18 Years ~ 60 Years | Frontage Clinical Services, Inc., Secaucus, New Jersey, United States |
221 | Not yet recruiting | the Safety and Efficacy of Meplazumab in Patients With COVID-19 | Covid19 | Drug: Meplazumab for Injection Drug: Sterile normal saline (0.9%) |
Phase 3 | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | INDUSTRY | 150 | All | 18 Years ~ 75 Years | |
220 | Recruiting | The Safety and Efficacy of Pyronaridine-artesunate (Pyramax® or Artecom®)in COVID-19 Patients | Covid19 | Drug: Artecom® (pyronaridine-artesunate) Drug: Placebo |
Phase 3 | Shin Poong Pharmaceutical Co. Ltd. | INDUSTRY | 402 | All | 19 Years | De La Salle University Medical Center, Dasmarinas, Gov, D. Mangubat St, 4114 Cavite, Philippines The Medical City, Pasig City, Ortigas Avenue, Barangay Ugong, Metro Manila, Philippines Lung Center of the Philippines, Quezon City, Quezon Avenue, Quezon City, 1100 Philippines, Philippines Philippine General Hospital, Manila, Taft Ave, Ermita, Manila, 1000 Metro, Philippines |